{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:12:53Z","timestamp":1788887573645,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-995601"],"award-info":[{"award-number":["R-995601"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009148","name":"Queen Mary University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2023-02305"],"award-info":[{"award-number":["2023-02305"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["22 2092"],"award-info":[{"award-number":["22 2092"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009806","name":"Ulla and Gustaf af Ugglas Foundation","doi-asserted-by":"publisher","award":["2023-02503"],"award-info":[{"award-number":["2023-02503"]}],"id":[{"id":"10.13039\/501100009806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005874","name":"Universit\u00e0 degli Studi G. d'Annunzio Chieti - Pescara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000779","name":"University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ard.2025.03.014","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:18:27Z","timestamp":1746429507000},"page":"1549-1560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies"],"prefix":"10.1016","volume":"84","author":[{"given":"Sabreen","family":"Alabbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Tacconelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5676-1644","authenticated-orcid":false,"given":"Mirjam","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilija","family":"Oke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Kvarnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"De Michele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia Di","family":"Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1419-2691","authenticated-orcid":false,"given":"Paola","family":"Patrignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4041-4729","authenticated-orcid":false,"given":"Helena","family":"Idborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Johan","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl_1","key":"10.1016\/j.ard.2025.03.014_bib0001","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.03.014_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.ard.2025.03.014_bib0003","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ard.2025.03.014_bib0004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5114\/reum.2018.77971","article-title":"Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology","volume":"56","author":"Kucharz","year":"2018","journal-title":"Reumatologia"},{"key":"10.1016\/j.ard.2025.03.014_bib0005","doi-asserted-by":"crossref","unstructured":"Ogdie A, De Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020;6(1):e001042. doi:10.1136\/rmdopen-2019-001042","DOI":"10.1136\/rmdopen-2019-001042"},{"issue":"4","key":"10.1016\/j.ard.2025.03.014_bib0006","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.03.014_bib0007","doi-asserted-by":"crossref","unstructured":"Tian Z, Kearsley-Fleet L, Galloway J, Watson K, BSRBR-RA Contributors Group, Lunt M, et al. Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK. Rheumatology (Oxford). 2025;64:1453-8. doi:10.1093\/rheumatology\/keae279","DOI":"10.1093\/rheumatology\/keae279"},{"issue":"1","key":"10.1016\/j.ard.2025.03.014_bib0008","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO Pharmacovigilance Database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.ard.2025.03.014_bib0009","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.ard.2025.03.014_bib0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.ard.2025.03.014_bib0011","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: a clinical pharmacology review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ard.2025.03.014_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40744-024-00671-4","article-title":"Safety profile of upadacitinib up to 5 years in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis: an integrated analysis of clinical trials","volume":"11","author":"Burmester","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.03.014_bib0013","article-title":"Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition","volume":"10","author":"Nikolopoulos","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.ard.2025.03.014_bib0014","first-page":"1485","article-title":"Pharmacology of inhibitors of Janus kinases\u2014part 1: pharmacokinetics","volume":"20","author":"Eichner","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ard.2025.03.014_bib0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fphar.2020.00613","article-title":"Anti-inflammatory properties of chemical probes in human whole blood: focus on prostaglandin E2 production","volume":"11","author":"Bergqvist","year":"2020","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.ard.2025.03.014_bib0016","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1021\/cr2002992","article-title":"Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis","volume":"111","author":"Smith","year":"2011","journal-title":"Chem Rev"},{"issue":"4","key":"10.1016\/j.ard.2025.03.014_bib0017","first-page":"661","article-title":"COX-2 is not involved in thromboxane biosynthesis by activated human platelets","volume":"50","author":"Patrignani","year":"1999","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"10.1016\/j.ard.2025.03.014_bib0018","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbalip.2014.09.016","article-title":"Cyclooxygenase inhibitors: from pharmacology to clinical read-outs","volume":"1851","author":"Patrignani","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.ard.2025.03.014_bib0019","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ard.2025.03.014_bib0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pr.59.3.1","article-title":"Membrane prostaglandin E synthase-1: a novel therapeutic target","volume":"59","author":"Samuelsson","year":"2007","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.ard.2025.03.014_bib0021","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ard.2025.03.014_bib0042","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.apha.2022.12.001","article-title":"Cyclooxygenases and platelet functions","volume":"97","author":"Bruno","year":"2023","journal-title":"Adv Pharmacol"},{"issue":"22","key":"10.1016\/j.ard.2025.03.014_bib0035","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2025.03.014_bib0024","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0022-3565(25)24061-7","article-title":"Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases","volume":"271","author":"Patrignani","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"3-4","key":"10.1016\/j.ard.2025.03.014_bib0023","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.ard.2025.03.014_bib0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1124\/jpet.119.259382","article-title":"Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium\u2013induced colitis in mice","volume":"370","author":"Sacco","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.ard.2025.03.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"Supp 1","key":"10.1016\/j.ard.2025.03.014_bib0027","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1080\/13547500500215084","article-title":"Isoprostanes and other markers of peroxidation in atherosclerosis","volume":"10","author":"Patrignani","year":"2005","journal-title":"Biomarkers."},{"issue":"1","key":"10.1016\/j.ard.2025.03.014_bib0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-3565(25)12087-9","article-title":"Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man","volume":"275","author":"Wang","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ard.2025.03.014_bib0029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI111703","article-title":"Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis","volume":"75","author":"Remuzzi","year":"1985","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ard.2025.03.014_bib0033","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0016-5085(86)90921-2","article-title":"Altered renal and platelet arachidonic acid metabolism in cirrhosis","volume":"90","author":"Laffi","year":"1986","journal-title":"Gastroenterology"},{"issue":"25","key":"10.1016\/j.ard.2025.03.014_bib0034","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ard.2025.03.014_bib0030","unstructured":"Singh ND. Sample size calculator for comparing paired differences [Internet]. [accessed 2024 Nov 5]. Available from: https:\/\/statulator.com\/SampleSize\/ss2PM.html"},{"issue":"24","key":"10.1016\/j.ard.2025.03.014_bib0031","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1111\/bph.14827","article-title":"Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone","volume":"176","author":"Larsson","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ard.2025.03.014_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-3848(85)90027-1","article-title":"Physiologic variables affecting thromboxane B2 production in human whole blood","volume":"37","author":"Alessandrini","year":"1985","journal-title":"Thromb Res"},{"issue":"7329","key":"10.1016\/j.ard.2025.03.014_bib0036","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ard.2025.03.014_bib0037","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cei.12970","article-title":"Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production","volume":"189","author":"Mitchell","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ard.2025.03.014_bib0038","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.redox.2017.08.021","article-title":"Regulation of platelet activation and thrombus formation by reactive oxygen species","volume":"14","author":"Qiao","year":"2018","journal-title":"Redox Biol"},{"issue":"11","key":"10.1016\/j.ard.2025.03.014_bib0039","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1172\/JCI59291","article-title":"Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane","volume":"121","author":"Tang","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ard.2025.03.014_bib0022","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2217\/clp.10.11","article-title":"Thromboxane and the thromboxane receptor in cardiovascular disease","volume":"5","author":"Smyth","year":"2010","journal-title":"Clin Lipidol"},{"issue":"10","key":"10.1016\/j.ard.2025.03.014_bib0041","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.03.014_bib0040","first-page":"S241","article-title":"Antiplatelet drugs","volume":"147","author":"Born","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.ard.2025.03.014_bib0043","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","article-title":"Role of aspirin in primary prevention of cardiovascular disease","volume":"16","author":"Patrono","year":"2019","journal-title":"Nat Rev Cardiol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:13:40Z","timestamp":1763662420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725008829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0003496725008829"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.03.014","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}